Ashwagandha cuts cortisol 27, 30% in RCTs. Rhodiola reduces fatigue at 200, 680 mg/day. Here's what the evidence actually says about combining them.
From this read
Both ashwagandha and rhodiola have individual RCT-level evidence behind them, ashwagandha showing cortisol reductions of around 27, 30% in stressed adults at 300, 600 mg/day, rhodiola showing meaningful reductions in fatigue scores at 200, 680 mg/day. The honest answer on combining them is that the direct combination data is thin. Here's what the research actually supports, and where I'm extrapolating.
What the evidence actually shows
Let me be direct about something before going any further. Most articles on this topic write as though there's a stack of rigorous trials specifically testing the ashwagandha and rhodiola combination. There isn't, not yet, not at the scale that would let me make confident quantitative claims about additive effects. What exists is solid individual evidence for each plant, a plausible biological rationale for combining them, and some early work on botanical hybrid preparations that suggests the direction is worth exploring.
On ashwagandha individually: a 60-person double-blind RCT found that 300 mg twice daily of a high-concentration root extract produced a statistically significant reduction in serum cortisol (p < 0.001) and improved scores on the Perceived Stress Scale compared to placebo. That's a real signal in a real population. On rhodiola: Sarris et al. (2013) reviewed clinical studies and found rhodiola rosea had meaningful evidence for reducing fatigue and stress-related symptoms, with effect sizes that held up across multiple trials, though the authors noted study quality was variable.
The combination question gets more interesting when you look at how researchers are starting to think about botanical hybrid preparations. Panossian et al. (2024) published a thorough review on botanical hybrid preparations, arguing that multi-herb adaptogen combinations may produce additive or complementary effects through distinct but overlapping stress-response pathways. The paper stops short of providing combination-specific effect sizes, because the clinical data doesn't yet exist at that level, but the mechanistic case is laid out carefully. I find it persuasive, with appropriate caveats.
Sánchez et al. (2023) conducted a systematic integrative review of adaptogens and depression-related outcomes. They found consistent signals across both ashwagandha and rhodiola for mood and stress markers, and noted that the rationale for combining adaptogens with complementary mechanisms was biologically coherent, even where direct combination trials were absent. That's an honest framing. I'm applying the same standard here.
If you want a deeper grounding in the cortisol physiology before reading further, the stress cortisol hub covers the HPA axis, cortisol rhythms, and what chronic stress actually does to your body at a cellular level.
The biology: what's happening when you take both
Ashwagandha and rhodiola appear to act on overlapping but distinct parts of the stress response. Understanding that distinction is what makes the combination interesting, not marketing language, just actual biology.
Ashwagandha's primary targets
Ashwagandha's active withanolides, particularly withaferin A and withanolide D, are thought to modulate the hypothalamic-pituitary-adrenal (HPA) axis. The HPA axis is the central stress-response system: it starts with a perceived threat, runs through the hypothalamus and pituitary, and ends with cortisol release from the adrenal glands. Ashwagandha may reduce the amplitude of that cortisol response. There's also evidence it interacts with GABA receptor activity, which would partly explain the anxiolytic signals seen in clinical data. Sarris et al. (2013) noted GABA-mimetic activity as a plausible mechanism in their review of plant-based anxiety interventions.
Rhodiola's primary targets
Rhodiola rosea's key bioactives, rosavins and salidroside, appear to work more on the sympathoadrenal system (the faster, adrenaline-driven stress arm) and on neuropeptide Y (NPY) signalling. NPY is a peptide released during stress that helps regulate the stress response and is associated with stress resilience. Asea et al. (2014) evaluated Hsp72 and NPY as characteristic markers of adaptogenic activity and found that rhodiola-class extracts produced measurable changes in NPY expression, a finding that helps explain rhodiola's particular profile around fatigue and acute stress rather than chronic cortisol elevation.
Rhodiola also appears to influence monoamine neurotransmitter systems, specifically serotonin, dopamine, and noradrenaline, through inhibition of monoamine oxidase (MAO). That's a different pathway from ashwagandha's HPA and GABA activity. Panossian et al. (2019) examined gene expression effects of adaptogenic extracts on eicosanoid signalling pathways and found both anti-inflammatory and stress-modulating activity, with different expression profiles between plant types, supporting the idea that they're not simply duplicating each other's mechanisms.
Why the combination is biologically plausible
If ashwagandha is primarily modulating the slow, chronic arm of the stress response (HPA axis, cortisol) and rhodiola is primarily modulating the fast, acute arm (sympathoadrenal, NPY, monoamines), then combining them covers more of the stress-response architecture than either does alone. That's the logic. It's mechanistically sound. The human data to confirm that the combination produces better outcomes than either alone, at matched doses, is still limited. I'd be overstating it to claim otherwise.
Dosing: what the clinical evidence actually supports
This matters more than most supplement articles acknowledge. Dose is everything. The studies that produced meaningful results used specific extracts at specific doses, and "ashwagandha" on a label tells you almost nothing without knowing the extract concentration and withanolide content.
For ashwagandha, the RCTs showing cortisol reduction have generally used KSM-66 or Sensoril standardised root extracts at 300, 600 mg/day. The 60-person trial referenced earlier used 300 mg twice daily (600 mg total) of KSM-66. A separate 8-week trial in chronically stressed adults used 300 mg once daily and still showed significant cortisol reduction. Going below 300 mg of a standardised extract, or using an unstandardised powder, puts you in territory where the evidence doesn't follow.
For rhodiola, Bucci (2000) reviewed selected herbals and exercise/stress performance and noted that rhodiola studies showing anti-fatigue effects typically used doses between 200 mg and 680 mg/day of standardised extracts (typically standardised to 3% rosavins and 1% salidroside). The acute stress-reduction studies tend to cluster around 200, 400 mg; the longer-term fatigue studies often use the higher end of that range.
When combining both, the clinical logic would suggest using each at doses that showed individual efficacy, so roughly 300, 600 mg ashwagandha and 200, 400 mg rhodiola. I haven't seen a well-powered RCT that has tested this specific combination at these doses head-to-head against placebo or individual arms. That trial needs to exist. Until it does, the combination dose is an extrapolation from individual evidence.
For context: the KōJō Daily Formula doesn't currently include ashwagandha or rhodiola, the formula focuses on foundational nutrients and compounds with strong individual evidence, including 500 mg Vitamin C [GB-NHC: Vitamin C contributes to the reduction of tiredness and fatigue; authorised at ≥80 mg/day], and ingredients like Glycine (2,000 mg) and Taurine (2,000 mg), where research is ongoing and large-scale human trials remain limited. I mention this not to push the product, but because it illustrates how I think about dose thresholds and evidence standards when formulating.
Cortisol specifically: what the data says
Cortisol is the most commonly cited target when people ask about the ashwagandha and rhodiola combination. It's worth being precise about what "lower cortisol" actually means in this context, because cortisol isn't simply bad, and the studies aren't showing that these herbs suppress cortisol wholesale.
What the better ashwagandha trials show is a reduction in stress-elevated cortisol, specifically, morning serum cortisol in adults who scored high on perceived stress questionnaires at baseline. The 27, 30% reductions cited in those trials are against elevated starting points. In people with normal cortisol rhythms, the effect is likely smaller or absent. That's an important distinction.
Rhodiola's cortisol data is less direct. Most rhodiola trials measure fatigue, mood, and cognitive performance rather than serum cortisol specifically. The mechanism via NPY and sympathoadrenal modulation suggests it's working earlier in the stress cascade rather than at the cortisol output stage, which again points to the two plants potentially addressing different parts of the same problem.
If you're specifically concerned about elevated cortisol at night, a distinct pattern from daytime stress response, I'd point you to the article on high nighttime cortisol levels what the evidence shows, which goes into the specific physiology and what the evidence says about interventions.
Cognitive effects: the nootropic angle
There's a growing body of interest in both plants for cognitive function, not just stress. Malík et al. (2023) reviewed nootropic herbs as potential cognitive enhancers and included both ashwagandha and rhodiola in their analysis. The review found evidence for memory, attention, and processing speed benefits, but noted that most studies are small, and that it's difficult to disentangle whether cognitive improvements are a direct effect or secondary to reduced stress and fatigue.
That's an honest read of the data. Stress impairs working memory, attention, and processing speed, so if an intervention reduces stress, cognitive performance may improve as a downstream consequence rather than through a direct nootropic mechanism. Both explanations could be true simultaneously. I don't think it matters much practically, but it matters for how you interpret the claims.
If you're interested in the broader cognitive support picture, the article on omega 3 brain supplement uk what the evidence shows 1 covers DHA specifically, a nutrient with a different and more direct mechanism for cognitive function.
Adaptogen safety and who should be cautious
Both ashwagandha and rhodiola have reasonable short-term safety profiles in healthy adults. The clinical trials, typically 8, 12 weeks, haven't flagged serious adverse events at the doses used. That said, there are populations where caution is warranted.
Ashwagandha is a nightshade-family plant (Solanaceae) and has been associated with rare cases of liver injury in case reports, though causality is difficult to establish. People with thyroid conditions should be aware that ashwagandha may influence thyroid hormone levels, the evidence is mixed, but it's worth knowing. Sulaiman et al. (2022) reviewed adaptogenic constituents and noted that withanolides have biological activity beyond stress modulation, including effects on cellular signalling pathways, which is relevant context for anyone on medication or with a chronic condition.
Rhodiola is generally considered mild in terms of side effects. Some people report mild stimulant-like effects, restlessness or difficulty sleeping, particularly at higher doses or when taken late in the day. This makes dosing timing relevant: rhodiola is typically better taken in the morning.
Panossian et al. (2023) reviewed adaptogens in the context of immune support and noted that while the general safety profile is favourable, individual variation in response is real and herb-drug interactions, particularly with immunosuppressants and CNS-active medications, are plausible and under-studied.
What "adaptogenic" actually means, and why it matters here
The word "adaptogen" gets thrown around loosely. It has a specific pharmacological definition, developed by Soviet researchers in the 1960s and refined since: a substance that produces a non-specific resistance to stress, is non-toxic at normal doses, and normalises physiological function without over-stimulating or over-suppressing. Asea et al. (2014) proposed Hsp72 and NPY as molecular markers that could be used to verify adaptogenic activity, a useful step towards making the category more scientifically rigorous rather than purely descriptive.
Both ashwagandha and rhodiola meet the classical definition. Panossian et al. (2023) and Panossian et al. (2019) have been among the more rigorous voices in the field pushing for mechanistic specificity, which is why I keep citing that group. They're not cheerleaders; they're asking the hard questions about what these plants actually do at a molecular level.
Why does this matter for the combination question? Because if both plants are genuine adaptogens acting through distinct but complementary mechanisms, the case for combining them is stronger than if "adaptogen" is just a marketing label applied to anything vaguely calming. The mechanistic specificity matters.
Frequently asked questions
Is there direct clinical evidence for the ashwagandha and rhodiola combination specifically?
The human data on this specific combination is thin and I'd be overstating it to claim otherwise. What exists is strong individual evidence for each plant and a mechanistic rationale for combining them, reviewed in Panossian et al. (2024). A well-powered RCT testing the combination head-to-head against individual arms and placebo hasn't been published at the time of writing.
Can you take ashwagandha and rhodiola at the same time, or should they be taken separately?
There's no known pharmacological reason they can't be taken together. Rhodiola may have mild stimulating properties, so some people prefer it in the morning; ashwagandha is generally taken with food and is often split into morning and evening doses in the trials that showed cortisol reduction. Timing them together in the morning is a reasonable practical approach, though individual response varies.
How long does it take to notice any effect from either adaptogen?
The RCTs that showed cortisol and stress score reductions with ashwagandha ran for 8, 12 weeks. Rhodiola's acute anti-fatigue effects have been observed within single doses in some studies, as noted in Sarris et al. (2013), but sustained effects on stress markers take longer. Expecting results in under four weeks is probably unrealistic for the cortisol-related endpoints.
Do these plants affect sleep?
Ashwagandha has some trial evidence for sleep quality improvements in stressed adults, plausibly via GABA-related activity. Rhodiola, taken late in the day, may interfere with sleep in sensitive individuals due to mild stimulant-adjacent effects. If sleep is your primary concern, the evidence points more clearly towards ashwagandha than rhodiola, and timing matters. See also the article on high nighttime cortisol levels what the evidence shows for related context.
Are there any interactions with medications I should know about?
Both plants have plausible interactions with CNS-active medications, thyroid medications, and immunosuppressants, though large-scale interaction data is limited. Panossian et al. (2023) noted that herb-drug interactions for adaptogens are under-studied. Anyone on prescription medication should review this with their prescriber before adding either plant at therapeutic doses.
What extract standardisation should I look for on the label?
For ashwagandha, look for KSM-66 or Sensoril, these are the extracts used in the published RCTs, standardised to withanolide content (typically 5% for KSM-66). For rhodiola, look for standardisation to 3% rosavins and 1% salidroside. An unstandardised ashwagandha or rhodiola powder may contain highly variable active compound concentrations, making it difficult to replicate trial conditions.
My honest take
I started looking at this combination because a lot of people ask about it, and because I wanted to know whether the enthusiasm was warranted or whether it was another case of two individually interesting things being combined on the basis of vibes and marketing rather than evidence.
My honest read: the individual evidence for both plants is more solid than I expected going in. The ashwagandha cortisol data in particular, 27, 30% reductions in stressed adults in double-blind RCTs, is a real signal. Rhodiola's anti-fatigue evidence is also more consistent than I'd previously credited it with being. Sánchez et al. (2023) and Malík et al. (2023) both gave me more confidence in these plants than I had before I read them carefully.
The combination specifically? The mechanistic rationale is genuinely compelling, two plants acting on distinct but complementary parts of the stress architecture. Panossian et al. (2024) make this case carefully and without overstating it. But I can't point you to a rigorous RCT that tested the combination and showed it outperforms either plant alone. That study doesn't exist yet in a form I'd stake a claim on.
So where does that leave me? I think the combination is a reasonable choice for someone who wants to address both the acute and chronic dimensions of stress response, rhodiola for the fast, acute arm; ashwagandha for the slower, cortisol-mediated arm. I'd use standardised extracts at doses that match the RCT evidence. I'd give it at least eight weeks. And I'd be honest with myself that I'm partly extrapolating from individual evidence rather than reading from a combination-specific trial.
That's not a reason not to try it. It's just the accurate framing. I'd rather tell you that than pretend the combination data is more settled than it is.
This article is for informational purposes only and does not constitute medical advice. Consult your healthcare provider before starting any supplement regimen.
References (9 studies)
- Malík et al. (2023), Nootropic Herbs, Shrubs, and Trees as Potential Cognitive Enhancers. PMID 36987052.
- Panossian et al. (2023), The Role of Adaptogens in Prophylaxis and Treatment of Viral Respiratory Infections. PMID 32911682.
- Bucci (2000), Selected herbals and human exercise performance. PMID 10919969.
- Sánchez et al. (2023), Adaptogens on Depression-Related Outcomes: A Systematic Integrative Review and Rationale of Synergism with Physical Activity. PMID 37047914.
- Panossian et al. (2024), Review on Botanical Hybrid Preparations in Phytomedicine and Phytotherapy Research. PMID 38675443.
- Sulaiman et al. (2022), Systemic and Anticancer Potential of Adaptogenic Constituents Isolated from Traditional Herbs. PMID 35400325.
- Sarris et al. (2013), Plant-based medicines for anxiety disorders, part 2: a review of clinical studies with supporting preclinical evidence. PMID 23653088.
- Panossian et al. (2019), Effects of anti-inflammatory and adaptogenic herbal extracts on gene expression of eicosanoids signalling pathways in isolated brain cells. PMID 30987861.
- Asea et al. (2014), Evaluation of molecular chaperons Hsp72 and neuropeptide Y as characteristic markers of adaptogenic activity of plant extracts. PMID 23920279.
